CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 26 enrolled
Drug / intervention
Dapagliflozin +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02518945
NCT02518945Phase 3Completed
CompareCT.gov

Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes. A Randomized Clinical Trial

University at Buffalo·interventional·Posted Aug 10, 2015·Updated Jan 24, 2024

In Brief

A Phase 3 clinical trial evaluating Dapagliflozin, Insulin, and 2 other interventions for Type 1 Diabetes Mellitus. Completed, enrolled 26 participants across 1 site.

Detailed Summary

This is a single center, prospective, randomized, double blinded placebo controlled study conducted I patients with type 1 diabetes.The aim of this study is to examine the additive effects of GLP-1 agonist and SGLT2 inhibitor in patients with type 1 diabetes in terms of possible improved glycemic control, reduced glycemic variability, reduced insulin dosages, additional effects of weight loss and blood pressure reduction.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes Mellitus
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 10, 2015
Enrollment StartAug 1, 2015
Primary CompletionDec 1, 2015
Study CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 10.9 years ago

Interventions

Dapagliflozindrug

Dapagliflozin or Farxiga is a SGLT-2 inhibitor

Insulindrug

Liraglutidedrug

Victoza(Liraglutide) is a GLP-1 agent.

Dapagliflozin placebodrug

Dapagliflozin placebo looking similar to active drug Dapagliflozin in external appearance but not containing active ingredient dapagliflozin